Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. doi:
10.1056/NEJMoa1504627.
Bulut I, Meral M, Kaynar H, Pirim I, Bilici M, Gorguner M. Analysis of HLA class I and II alleles regarding to lymph node and dis tant
m etastasis in patients with non-small cell lung cancer. Lung Cancer. 2009;66(2):231‐6.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ,
Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhan g J, Lunceford JK, Rangwala R,
Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the Treatment of Non-Small-
Cell Lung Cancer. N Engl J Med. 2015;372(21):2018-28. doi: 10.1056/NEJMoa1501824.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch
C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 2004;22(9):1589‐97.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR,
Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, , based on
November 2014 SEER data submission, posted to the SEER web site, April 2015
Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B,
Thor Straten P, Mellemgaard A, Andersen MH, Svane IM.
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived
from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560.
Masucci GV, Andersson E, Villabona L, Helgadottir H, Bergfeldt K, Cavallo F, et al. Survival of the fittest or best adapted: HLA-
dependent tumor development. J Nucleic Acids Investig [Internet]. 1 mars 2010 [Accessed 23 sept 2013];1(1). Available at:
Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T, Ichiki Y, Yasuda M, So T, Takenoyama M, Sugio K, Nagashima
A, Yasumoto K. Clinical significance of HLA class I alleles on pos toperative prognosis of lung cancer patients in Japan. Lung Cancer.
2009;65(1):91‐7. doi: 10.1016/j.lungcan.2008.10.012.
Nemunaitis J, Cunningham, C ,Bender, J, Ishioka, G, Maples, P, Pappen, B, Stephenson, J, Morse, M, Mills, B, Greco, A, McCune, D,
Steis, R, Nugent, F, Khong, HT, Richards, D. Phase II
trial of a 10-epitope CTL vaccine, IDM-2101, in metastatic NSCLC patients:
Induction of immune responses and clinical efficacy. International Society for Biological Therapy of Cancer 2007, p 891-2.
Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H.
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell
lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16(8):620-4. doi: 10.1038/cgt.2009.15.
Nemunaitis J. et al,–T-cytotoxic specific immunotherapy in NSCLC with brain metastases. P2.01-003 - Abstract 1202 16th world
conference on lung cancer, September 2015
Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, Quan Man Chow L, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaeufl
M, Rodriguez O, Burgio MA, Fayette J, Gettinger SN, Harbison C, Dorange C, Graf Finckenstein F, Brahmer JR.
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ)
non-small cell lung cancer (NSCLC). J Clin Oncol 33; 2015 (suppl; abstr LBA109).
Rizvi N, Brahmer J, Ou SH et al. Safety and clinical activityof MEDI4736, an anti-programmed cell death-ligand (PD-L1) antibody in
patients with non-small-cell lung cancer. J Clin Oncol 2015; 33 (suppl; abstr 8032)
Rizvi NA, Garon E, Leighl N et al. Optimizing PD-L1 as biomarker of response with pembrolizumab as first-line therapy for PD-L1
positive metastatic non-small cell lung cancer: updated data from KEYNOTE-001. J Clin Oncol 2015; 33 (suppl; abstr 8026)
Page 70 / 469